Mitochondria‐targeted photodynamic therapy (Mt‐PDT), which enables the photogenerated cytotoxic oxygen species with fatal oxidative damage to block mitochondrial functions, has been considered as a promising method to enhance the anticancer effectiveness. Aiming at the challenges of PDT, in the past few decades, numerous mitochondria‐targeting molecular agents have been developed to boost the PDT efficacy via directly destroying the mitochondria or activating mitochondria‐mediated cell death pathways. Herein, a review for recent advances of Mt‐PDT is highlighted including: mitochondrial targeting design principles and strategies, therapeutic performance of mitochondria‐targeted agents‐mediated PDT as well as the agent‐free Mt‐PDT. In addition, it puts together the achievements of the combinatory mitochondria‐anchoring PDT and other anticancer strategies, demonstrating the advantages provided by Mt‐PDT. The existing challenges are discussed and future settlements for the development of mitochondria‐specific agents are also forecasted.

中文翻译：

---

用于光动力癌症治疗的线粒体特异药物：提高疗效的关键决定因素

线粒体靶向光动力疗法（Mt-PDT）使光生的具有致命性氧化损伤的细胞毒性氧种能够阻断线粒体功能，被认为是增强抗癌效果的一种有前途的方法。针对PDT的挑战，在过去的几十年中，已经开发了许多靶向线粒体的分子药物，可通过直接破坏线粒体或激活线粒体介导的细胞死亡途径来提高PDT的功效。本文重点介绍了Mt-PDT的最新进展，包括：线粒体靶向设计原则和策略，线粒体靶向药物介导的PDT的治疗性能以及无药物的Mt-PDT。此外，它结合了结合线粒体锚定PDT的成就和其他抗癌策略，证明了Mt-PDT的优势。讨论了现有挑战，并预测了针对线粒体特异试剂发展的未来解决方案。